A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer.

Trial Profile

A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2018

At a glance

  • Drugs DPX 0907 (Primary)
  • Indications Breast cancer; Ovarian cancer; Prostate cancer
  • Focus Adverse reactions
  • Sponsors IMV
  • Most Recent Events

    • 03 May 2018 According to an IMV media release, Immunovaccine has changed its name to IMV.
    • 06 Aug 2012 Results were published in the Journal of Translational Medicine, according to an Immunovaccine media release. Results were also reported in the media release.
    • 04 Jun 2012 Results have been presented at ASCO-2012 according to an Immunovaccine media release. Results were also summarised in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top